Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Sara Piccini, Giuseppe Favacchio, Cristina Panico, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 20
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
Hannah Moll, E.A. Frey, Philipp A. Gerber, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102661-102661
Open Access | Times Cited: 20
Chitosan based surface modulation of core-shell nanoparticles for oral delivery of exenatide via balancing mucus penetration and cellular uptake
Yiyao Li, H. Tian, Han Zeng, et al.
International Journal of Pharmaceutics (2025) Vol. 672, pp. 125319-125319
Closed Access | Times Cited: 2
Evidence that tirzepatide protects against diabetes-related cardiac damages
Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
Sergio Fazio, Valentina Mercurio, Loredana Tibullo, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 12
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study
William van Houtum, Patrick Schrömbges, Hanan Amadid, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 8, pp. 1749-1768
Open Access | Times Cited: 12
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Magda Wojtara, A Mazumder, Yusra Syeda, et al.
Advances in Medicine (2023) Vol. 2023, pp. 1-7
Open Access | Times Cited: 18
Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Sara Coluzzi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3054-3054
Open Access | Times Cited: 6
Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists
Hsuan-Wen Lai, Chun Yin See, Jui‐Yi Chen, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Glucagon-like peptide-1 agonists in cardiovascular diseases, a bibliometric analysis from inception to 2023
Abinash Mahapatro, Ali Bozorgi, Sri Usha Jeevani Obulareddy, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 11, pp. 6602-6618
Open Access | Times Cited: 6
The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
Janet B. McGill, Irl B. Hirsch, Christopher G. Parkin, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1085-1098
Open Access | Times Cited: 5
Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone
Eugene E. Wright, Gregory J. Roberts, Joyce Chuang, et al.
Diabetes Technology & Therapeutics (2024) Vol. 26, Iss. 10, pp. 754-762
Closed Access | Times Cited: 5
Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists
Sara Piccini, Giuseppe Favacchio, Emanuela Morenghi, et al.
Diabetes Research and Clinical Practice (2024) Vol. 212, pp. 111689-111689
Open Access | Times Cited: 5
Coronary artery disease
M. De Alwis, Namal Wijesinghe
Journal of the Ceylon College of Physicians (2023) Vol. 54, Iss. 2, pp. 153-158
Open Access | Times Cited: 12
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonist Use During the First Trimester in Pregnant Women With Type 2 Diabetes
Muhammad Hanif, Allison G. Hays, JAI SIVANANDAN NAGARAJAN, et al.
The American Journal of Cardiology (2025)
Closed Access
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
Tyler J. Dunn, Yong Zhu, Noelle N. Gronroos, et al.
Diabetes Research and Clinical Practice (2025), pp. 112162-112162
Open Access
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
Sadiya S. Khan, Chiadi E. Ndumele, Dhruv S. Kazi
JAMA (2024)
Closed Access | Times Cited: 3
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes
Huilin Tang, Ying Lü, William T. Donahoo, et al.
Annals of Internal Medicine (2025)
Closed Access
Knowing Well, Being Well: well-being born of understanding: Access to GLP-1s: Where Do Employers Fit in?
Mary T. Imboden
American Journal of Health Promotion (2025) Vol. 39, Iss. 5, pp. 828-843
Closed Access
Glucagon-Like Peptide 1 Receptor Agonists and the Deepening Health Equity Divide in America
Kateri J. Spinelli, Allison H. Oakes
American Journal of Health Promotion (2025) Vol. 39, Iss. 5, pp. 832-836
Closed Access
The impact of GLP-1 signalling on the energy metabolism of pancreatic islet β-cells and extrapancreatic tissues
Leah A. Peart, Matthew Draper, Andrei I. Tarasov
Peptides (2024) Vol. 178, pp. 171243-171243
Closed Access | Times Cited: 2
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Yajnavalka Banerjee, Angelo Maria Patti, Rosaria Vincenza Giglio, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 8, pp. 108517-108517
Closed Access | Times Cited: 6
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 6
Use of continuous glucose monitoring when initiating glucagon‐like peptide‐1 receptor agonist therapy in insulin‐treated diabetes
Irl B. Hirsch, Christopher G. Parkin, Tricia Santos Cavaiola, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S7, pp. 17-26
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top